Comparative study to evaluate skin irritation and adhesion of Estradot® and Climara® in healthy postmenopausal women

Climacteric

Volumn 5, Issue 4, 2002, Pages 383-389

  Ibarra De Palacios, P ^a   Schmidt, G ^a   Sergejew, T ^a   Quebe Fehling, E ^a   Lockhart, L ^b   Krinsky, L ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Hill Top Research Inc   (United States)

^c South Florida Bioavailability Clinic   (United States)

Author keywords

Climara; Estradiol; Estradoil; Transdermal estradiol delivery; Transdermal patch

Indexed keywords

ESTRADIOL; ESTRADOT;

ADHESION; ADULT; AGED; ARTICLE; BIOAVAILABILITY; BLISTER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; ESTROGEN THERAPY; EXUDATE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PAPULE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SCORING SYSTEM; SKIN IRRITATION; SKIN MANIFESTATION;

EID: 0036969281     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.5.4.383.389     Document Type: Article

References (26)

1. Ginsburg J, Hardiman P, Okolo S. Hormone replacement therapy in general practice. Br Med J 1991;302:1601-2
2. Birkhaüser MH, Haenggi W. Benefits of different routes of administration. Int J Fertil Menopausal Stud 1994;39(Suppl 1):11-19
3. Grodstein F, Stampfer, MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75
4. Insogna K, Concato J, Henrich J. Boning up on estrogen: new options, new concerns. J Am Med Assoc 1996;276:1430-2
5. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987;317:1169-74
6. Schairer C, Adami HO, Hoover R, Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology 1997;8:59-65
7. Archer DF, Furst K, Tipping D, et al. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. Obstet Gynecol 1999;94:498-503
8. Cooper C, Stakkestad JA, Radowicki S, et al. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporosis Int 1999;9:358-66
9. Kuhl IL. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990;12:171-97
10. Aedo AR, Landgren BM, Diczfalusy E. Pharmacokinetics and biotransformation of orally administerd oestrone sulphate and oestradiol valerate in post-menopausal women. Maturitas 1990;12:333-43
11. Balfour JA, McTavish D. Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis. Drugs Aging 1992;2:487-507
12. Samsioe G. Hormone replacement therapy: expanding treatment options with transdermal delivery. Curr Ther Res Clin Exp 1999;60:161-7
13. Li C, Samsioe G, Wilaman K, et al. Effects of norethisterone acetate addition to estradiol in long term HRT. Maturitas 2000;36:139-52
14. Notelovitz M, Bachman GA, Lucking D. Evaluation of Menorest at dose strengths 37.5, 50, 75, 100 μg/day. Eur J Clin Res 1996;8:219-34
15. Studd JWW, McCarthy K, Zamblera D, et al. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study. Maturitas 1995;22:105-14
16. Studd JWW, McCarthy K, Zamblera D, et al. A double-blind, double-dummy, comparative study of Menorest 50® versus Premarin® 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss in patients with menopausal symptoms. Clin Drug Invest 1996;11:205-13
17. Pornel B, Genazzani AR, Costes D, et al. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomised, multicenter, parallel group study. Maturitas 1995;22:207-18
18. Sefaty D, Caulin F. Efficacy and tolerability of transdermal 17β-estradiol in patients with climacteric symptoms: dose titration according to individual choice. Curr Ther Res Clin Exp 1996;57:506-15
19. Studd J, Panay N, Zamblera D, Leather AT. HRT and long-term compliance: the efficacy and safety of Menorest. Int J Gynecol Obstet 1996;52 (Suppl 1):S21-5
20. Lübbert H, Nauert C. Continuous versus cyclical transdermal estrogen replacement therapy in post-menopausal women: influence on climacteric symptoms, body weight and bleeding pattern. Maturitas 1997;28:117-25
21. Cooper C, Stakkestad JA, Radowicki S, et al. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women. Osteoporosis Int 1999;9:358-66
22. Delmas PD, Pornel B, Felsenberg D, et al. A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women. Bone 1999;24:517-23
23. Andersson TL, Stehle B, Davidson B, Hoglund P. Drug concentration effect relationship of estradiol from two matrix transdermal delivery systems: Menorest® and Climara. Maturitas 2000;35:245-52
24. Andersson TL, Stehle B, Davidson B, Hoglund P. Bioavailability of estradiol from two matrix delivery systems: Menorest and Climara. Maturitas 2000;34:57-64
25. Novartis Pharma AG. A bioavailability study of two doses of Noven second generation estradiol transdermal system in healthy post-menopausal women. Report on Protocol 1012, Novartis Pharma AG, Basel, January 1997
26. Novartis Pharma AG. A multiple dose steady state bioequivalence study of two estradiol transdermal systems in healthy post-menopausal women. Report on Protocol 004. Novartis Pharma AG, Basel, March 1998